Bod Science Limited

Equities

BOD

AU0000181331

Pharmaceuticals

Market Closed - Australian S.E. 11:59:52 2023-11-22 pm EST 5-day change 1st Jan Change
0.024 AUD -7.69% Intraday chart for Bod Science Limited -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bod Science Announces Delay in Appendix 4D Lodgement MT
BOD Science Signs Supply Agreement in Medicinal Cannabis with Green Farmers MT
Bod Science Limited Enters into Supply Agreement with Green Farmers CI
Bod Science Receives AU$1.6 Million R&D Tax Refund; Shares Rise 8% MT
Bod Expects to Receive Funds from Antah Soon MT
Bod Science Delays Settlement of Tranche 1 of AU$2.1 Million Placement MT
Bod Science Raises AU$2.1 Million Via Share Placement; Shares Fall 43% MT
Bod Science Limited announced that it expects to receive AUD 2.05 million in funding CI
Australian Shares Retreat as Monthly CPI Indicator Rises MT
Bod Science Validates Greater Bioavailability of Drug Delivery Technology; Shares Rally 12% MT
Bod Science Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Bod Science Limited Announces Change of Principal Place of Business CI
Bod Science Completes Acquisition of Drug Delivery Technology; Shares Up 3% MT
Bod Australia Limited completed the acquisition of Aqua Phase Ltd. CI
Bod Science Validates Bioavailability of Aqua Phase Technology MT
Bod Science Signs Letter of Intent to Sell Medical Cannabis Products in Malaysia MT
US Debt Ceiling Caution Dampens Appetite for Australian Equities MT
Bod Australia Secures Ethics Approval for Drug Delivery Study; Shares Jump 10% MT
Bod Science Limited Announces David Baker Assumes an Additional Advisory Role to Support Management to Progress A Number of Commercial Initiatives CI
BOD Science Completes Recruiting for Phase IIb Clinical Trial of CBD Product MT
Bod Science Limited Announces Pharmacokinetic Study to Confirm the Bioavailability of Aqua Phase Submitted for Ethics Approval CI
Bod Science Completes Screening for Phase 2 Insomnia Trial MT
Bod Science Limited Provides the Update on Their Phase IIB Clinical trial CI
Bod Science Limited Updates on Acquisition of Aqua Phase Technology CI
BOD Science Gains Loan Facility from Radium Capital MT
Chart Bod Science Limited
More charts
Bod Science Limited is an Australia-based cannabis focused drug development and product innovation company. The Company is focused on progressing research and development with a defined clinical trial pathway to commercialize and deliver products for patients and consumers. The principal activities of the Company are the development and distribution of therapeutic medicinal cannabis products based on good manufacturing practice (GMP) certified cannabis extracts for medical markets in Australia and the United Kingdom, as well as the development of cannabidiol (CBD) and hemp products for consumer markets in Australia, the United Kingdom, Europe, and United States. The Company operates through three segments: medical, over the counter cannabidiol/Hemp (OTC CBD/Hemp) and OTC Herbals. The Company offers products for health and wellness, joint/muscle pain and general wellbeing, and stress/anxiety and sleep. The Company also owns the Aqua Phase delivery technology.
More about the company